Legal & General Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.64B Buy
12,159,427
+26,096
+0.2% +$5.79M 0.61% 20
2025
Q4
$2.77B Buy
12,133,331
+129,247
+1% +$29.4M 0.61% 17
2025
Q3
$2.78B Buy
12,004,084
+493,420
+4% +$100M 0.62% 19
2025
Q2
$2.14B Sell
11,510,664
-171,264
-1% -$31.8M 0.53% 23
2025
Q1
$2.45B Buy
11,681,928
+97,315
+0.8% +$18.9M 0.67% 20
2024
Q4
$2.06B Sell
11,584,613
-439,714
-4% -$80.8M 0.54% 25
2024
Q3
$2.37B Buy
12,024,327
+171,290
+1% +$32M 0.62% 21
2024
Q2
$2.03B Sell
11,853,037
-348,841
-3% -$57.8M 0.57% 22
2024
Q1
$2.22B Sell
12,201,878
-81,472
-0.7% -$14M 0.64% 21
2023
Q4
$1.9B Buy
12,283,350
+188,816
+2% +$27.5M 0.59% 23
2023
Q3
$1.8B Sell
12,094,534
-533,050
-4% -$78.3M 0.63% 23
2023
Q2
$1.7B Buy
12,627,584
+741,031
+6% +$109M 0.55% 25
2023
Q1
$1.89B Buy
11,886,553
+148,488
+1% +$22.7M 0.68% 21
2022
Q4
$1.9B Sell
11,738,065
-533,001
-4% -$81.7M 0.73% 20
2022
Q3
$1.65B Sell
12,271,066
-259,294
-2% -$37.2M 0.64% 24
2022
Q2
$1.92B Buy
12,530,360
+476,257
+4% +$72.8M 0.68% 22
2022
Q1
$1.95B Buy
12,054,103
+784,446
+7% +$114M 0.59% 20
2021
Q4
$1.53B Sell
11,269,657
-373,125
-3% -$44.1M 0.46% 31
2021
Q3
$1.26B Buy
11,642,782
+463,730
+4% +$53M 0.41% 43
2021
Q2
$1.26B Buy
11,179,052
+193,109
+2% +$21.7M 0.42% 40
2021
Q1
$1.19B Sell
10,985,943
-294,397
-3% -$31.5M 0.44% 38
2020
Q4
$1.21B Buy
11,280,340
+451,897
+4% +$43.4M 0.47% 36
2020
Q3
$948M Sell
10,828,443
-319,749
-3% -$30.1M 0.42% 45
2020
Q2
$1.09B Buy
11,148,192
+1,755,024
+19% +$155M 0.53% 33
2020
Q1
$716M Buy
9,393,168
+247,883
+3% +$21.1M 0.42% 46
2019
Q4
$810M Buy
9,145,285
+185,411
+2% +$15.4M 0.39% 48
2019
Q3
$678M Buy
8,959,874
+106,093
+1% +$7.27M 0.36% 50
2019
Q2
$644M Sell
8,853,781
-119,553
-1% -$9.4M 0.35% 53
2019
Q1
$723M Buy
8,973,334
+1,586,937
+21% +$130M 0.41% 45
2018
Q4
$681M Buy
7,386,397
+490,348
+7% +$43.1M 0.53% 32
2018
Q3
$652M Sell
6,896,049
-157,621
-2% -$14.9M 0.47% 37
2018
Q2
$654M Sell
7,053,670
-548,337
-7% -$53.6M 0.5% 32
2018
Q1
$720M Sell
7,602,007
-461,143
-6% -$50.7M 0.55% 32
2017
Q4
$780M Sell
8,063,150
-54,690
-0.7% -$5.15M 0.56% 33
2017
Q3
$721M Buy
8,117,840
+68,489
+0.9% +$5.21M 0.54% 32
2017
Q2
$584M Buy
8,049,351
+131,159
+2% +$8.82M 0.47% 39
2017
Q1
$516M Buy
7,918,192
+312,055
+4% +$19.6M 0.44% 40
2016
Q4
$476M Buy
7,606,137
+85,046
+1% +$5.19M 0.44% 40
2016
Q3
$474M Buy
7,521,091
+50,873
+0.7% +$3.29M 0.48% 40
2016
Q2
$462M Buy
7,470,218
+272,165
+4% +$16.6M 0.49% 42
2016
Q1
$411M Sell
7,198,053
-216,926
-3% -$12.1M 0.46% 41
2015
Q4
$439M Buy
7,414,979
+60,181
+0.8% +$3.47M 0.5% 40
2015
Q3
$400M Buy
7,354,798
+197,847
+3% +$12.9M 0.49% 39
2015
Q2
$481M Buy
7,156,951
+587,045
+9% +$38.3M 0.56% 35
2015
Q1
$385M Sell
6,569,906
-11,078
-0.2% -$669K 0.46% 45
2014
Q4
$431M Sell
6,580,984
-216,511
-3% -$13.6M 0.51% 38
2014
Q3
$393M Sell
6,797,495
-158,784
-2% -$8.82M 0.47% 42
2014
Q2
$393M Buy
6,956,279
+103,865
+2% +$5.45M 0.46% 43
2014
Q1
$352M Sell
6,852,414
-126,123
-2% -$6.37M 0.43% 49
2013
Q4
$369M Sell
6,978,537
-30,618
-0.4% -$1.5M 0.45% 49
2013
Q3
$314M Sell
7,009,155
-37,262
-0.5% -$1.65M 0.41% 54
2013
Q2
$291M Buy
+7,046,417
New +$308M 0.4% 53

Other funds holding ABBV

Legal & General Group's ABBV Position: Q1 2026 in Review

Legal & General Group increased its AbbVie (ABBV) stake by 0.22% in Q1 2026, buying an estimated $5.79M and bringing the position to 12,159,427 shares worth $2.64B. The position accounts for 0.61% of the portfolio, ranked #20.

Legal & General Group first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.78B in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Legal & General Group held 12,159,427 shares of AbbVie worth $2.64B as of Q1 2026.
  • Legal & General Group bought 26,096 AbbVie shares in Q1 2026, an estimated $5.79M.
  • AbbVie made up 0.61% of Legal & General Group's portfolio in Q1 2026, its #20 holding.
  • Legal & General Group first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Legal & General Group's AbbVie position peaked at $2.78B in Q3 2025.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.